HK1072947A1 - Immunological methods and compositions for the treatment of alzheimer's disease - Google Patents
Immunological methods and compositions for the treatment of alzheimer's diseaseInfo
- Publication number
- HK1072947A1 HK1072947A1 HK05105780.8A HK05105780A HK1072947A1 HK 1072947 A1 HK1072947 A1 HK 1072947A1 HK 05105780 A HK05105780 A HK 05105780A HK 1072947 A1 HK1072947 A1 HK 1072947A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disease
- alzheimer
- compositions
- treatment
- immunological methods
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001900 immune effect Effects 0.000 title 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37391402P | 2002-04-19 | 2002-04-19 | |
PCT/CA2003/000502 WO2003089460A1 (en) | 2002-04-19 | 2003-04-07 | Immunological methods and compositions for the treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1072947A1 true HK1072947A1 (en) | 2005-09-16 |
Family
ID=29251102
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05105780.8A HK1072947A1 (en) | 2002-04-19 | 2005-07-08 | Immunological methods and compositions for the treatment of alzheimer's disease |
HK11113133.8A HK1158665A1 (zh) | 2002-04-19 | 2005-07-08 | 用於治療阿爾茨海默氏病的免疫方法及組合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11113133.8A HK1158665A1 (zh) | 2002-04-19 | 2005-07-08 | 用於治療阿爾茨海默氏病的免疫方法及組合物 |
Country Status (18)
Country | Link |
---|---|
US (5) | US20030232758A1 (ja) |
EP (2) | EP2330113B1 (ja) |
JP (3) | JP4662719B2 (ja) |
KR (1) | KR100994748B1 (ja) |
CN (1) | CN100360555C (ja) |
AT (1) | ATE514707T1 (ja) |
AU (1) | AU2003218560B2 (ja) |
CA (1) | CA2481952C (ja) |
ES (1) | ES2368907T3 (ja) |
HK (2) | HK1072947A1 (ja) |
IL (3) | IL164643A0 (ja) |
MX (1) | MXPA04010255A (ja) |
NO (2) | NO335192B1 (ja) |
NZ (1) | NZ536064A (ja) |
PL (1) | PL209696B1 (ja) |
SG (1) | SG173214A1 (ja) |
WO (1) | WO2003089460A1 (ja) |
ZA (1) | ZA200408811B (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
CA2504349A1 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid |
US20050106626A1 (en) * | 2002-10-20 | 2005-05-19 | George Pieczenik | Ligand binding of amyloid peptide protein epitope |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US8193250B2 (en) | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
EP1820019A4 (en) * | 2004-11-12 | 2008-05-14 | Pfizer | METHOD FOR MEASURING BETA-AMYLOID PEPTIDES |
JP5486808B2 (ja) | 2005-11-30 | 2014-05-07 | アッヴィ・インコーポレイテッド | アミロイドベータタンパク質に対するモノクローナル抗体及びその使用 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
DK2361638T3 (en) | 2005-12-12 | 2014-03-03 | Ac Immune Sa | Beta-1-42-specific monoclonal antibodies with therapeutic properties |
JP5097695B2 (ja) * | 2006-02-22 | 2012-12-12 | 株式会社林原 | 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン |
NO347079B1 (no) | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Forbedrede protofibrilselektive antistoffer og anvendelse derav |
DE112007001030T5 (de) * | 2006-04-28 | 2009-02-26 | Kagoshima University | Amyloid-ß-Fibrillogenese-inhibierendes Peptid |
PL2046833T3 (pl) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2094730A4 (en) * | 2006-12-07 | 2010-08-04 | Mayo Foundation | METHODS AND MATERIALS ASSOCIATED WITH ANTI-AMYLOID ANTIBODIES |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
RS53174B (en) | 2007-10-05 | 2014-06-30 | Genentech Inc. | USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE |
EP2328908A4 (en) * | 2008-08-28 | 2012-11-28 | Univ New York State Res Found | TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF |
WO2010061899A1 (ja) * | 2008-11-28 | 2010-06-03 | 北興化学工業株式会社 | ワクチンを蓄積する形質転換ダイズ植物およびその利用 |
US8912145B2 (en) | 2008-11-28 | 2014-12-16 | Hokko Chemical Industry Co., Ltd. | Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease |
CN101797493B (zh) * | 2009-02-06 | 2014-05-21 | 上海抗体药物国家工程研究中心有限公司 | 一种在反应釜中制备亲和层析介质的方法 |
CN101486768B (zh) * | 2009-02-25 | 2012-05-30 | 吉林大学 | 一种用于治疗阿尔茨海默氏病的抗原蛋白及蛋白基因 |
US9256007B2 (en) * | 2009-04-21 | 2016-02-09 | Svv Technology Innovations, Inc. | Light collection and illumination systems employing planar waveguide |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
DE102011057019A1 (de) * | 2011-12-23 | 2013-06-27 | Forschungszentrum Jülich GmbH | Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen |
JP6130401B2 (ja) * | 2012-01-20 | 2017-05-17 | アンナプラガダ,アナンス | 医学画像を客観的に特徴付けるための方法および組成物 |
US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
DK2895512T3 (en) * | 2012-09-12 | 2018-10-15 | Neurimmune Holding Ag | Antibodies specific for human islet amyloid polypeptide (HIAPP) and uses thereof |
SI2906597T1 (sl) * | 2012-10-15 | 2020-08-31 | Medimmune Limited | Protitelesa za amiloid beta |
WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
PL3137094T3 (pl) * | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
MA53887A (fr) | 2014-07-10 | 2021-10-27 | Bioarctic Ab | Anticorps à liaison protofibrille a-bêta améliorée |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
WO2017098516A1 (en) * | 2015-12-10 | 2017-06-15 | The National Institute for Biotechnology in the Negev Ltd. | VARIANTS OF AMYLOID beta-PROTEIN PRECURSOR INHIBITOR DOMAIN |
NZ754020A (en) * | 2016-11-25 | 2022-11-25 | Genuv Inc | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same |
IL272773B1 (en) | 2017-08-22 | 2024-02-01 | Biogen Ma Inc | Pharmaceutical preparations containing anti-amyloid cell antibodies |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
AU2018355325A1 (en) | 2017-10-25 | 2020-05-07 | Ac Immune S.A. | Compositions of phosphorylated tau peptides and uses thereof |
EP3793583A4 (en) * | 2018-05-18 | 2022-03-09 | Université Laval | USE OF A NOD2 AGONIST FOR THE TREATMENT, PROPHYLAXIS AND/OR DELAYING THE ONSET OF MULTIPLE SCLEROSIS AND ALZHEIMER'S DISEASE |
US11684576B2 (en) * | 2019-02-08 | 2023-06-27 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
EP3927725A4 (en) * | 2019-02-22 | 2023-06-14 | Loyola Marymount University | AMYLOID PEPTIDE VARIANTS |
MA55902A (fr) | 2019-04-24 | 2022-03-16 | Ac Immune Sa | Administration hétérologue de vaccins tau |
TW202144387A (zh) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | 針對胰島澱粉樣多肽(iapp)的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑 |
CN115925987A (zh) * | 2022-02-28 | 2023-04-07 | 安域生物科技(杭州)有限公司 | 基于β-淀粉样蛋白修饰的抗原多肽及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
EP0708656B1 (en) * | 1993-04-27 | 2002-07-31 | United Biomedical, Inc. | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
WO1997007402A1 (en) | 1995-08-17 | 1997-02-27 | The Ontario Cancer Institute | Protein fibril assembly assay |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
EP1728423B1 (en) | 2000-06-20 | 2011-03-02 | The Governing Council Of The University Of Toronto | Transgenic animal model of neurodegenerative disorders |
US6310810B1 (en) | 2000-07-14 | 2001-10-30 | Raj Kumar Jain | High-speed sense amplifier |
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
-
2003
- 2003-04-07 AT AT03711746T patent/ATE514707T1/de not_active IP Right Cessation
- 2003-04-07 MX MXPA04010255A patent/MXPA04010255A/es unknown
- 2003-04-07 JP JP2003586180A patent/JP4662719B2/ja not_active Expired - Fee Related
- 2003-04-07 CA CA2481952A patent/CA2481952C/en not_active Expired - Fee Related
- 2003-04-07 SG SG2006073324A patent/SG173214A1/en unknown
- 2003-04-07 NZ NZ536064A patent/NZ536064A/en not_active IP Right Cessation
- 2003-04-07 CN CNB038088584A patent/CN100360555C/zh not_active Expired - Fee Related
- 2003-04-07 KR KR1020047016794A patent/KR100994748B1/ko not_active IP Right Cessation
- 2003-04-07 AU AU2003218560A patent/AU2003218560B2/en not_active Ceased
- 2003-04-07 EP EP10182139.5A patent/EP2330113B1/en not_active Expired - Lifetime
- 2003-04-07 EP EP03711746A patent/EP1497321B1/en not_active Expired - Lifetime
- 2003-04-07 PL PL373450A patent/PL209696B1/pl unknown
- 2003-04-07 ES ES03711746T patent/ES2368907T3/es not_active Expired - Lifetime
- 2003-04-07 WO PCT/CA2003/000502 patent/WO2003089460A1/en active Application Filing
- 2003-04-07 IL IL16464303A patent/IL164643A0/xx unknown
- 2003-04-10 US US10/411,544 patent/US20030232758A1/en not_active Abandoned
-
2004
- 2004-10-17 IL IL164643A patent/IL164643A/en not_active IP Right Cessation
- 2004-11-01 ZA ZA2004/08811A patent/ZA200408811B/en unknown
- 2004-11-18 NO NO20045021A patent/NO335192B1/no not_active IP Right Cessation
-
2005
- 2005-07-08 HK HK05105780.8A patent/HK1072947A1/xx not_active IP Right Cessation
- 2005-07-08 HK HK11113133.8A patent/HK1158665A1/zh not_active IP Right Cessation
- 2005-07-13 US US11/180,225 patent/US20090041771A1/en not_active Abandoned
-
2009
- 2009-01-15 IL IL196532A patent/IL196532A/en not_active IP Right Cessation
- 2009-10-30 JP JP2009251464A patent/JP5345920B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-29 US US13/434,205 patent/US20120315321A1/en not_active Abandoned
- 2012-11-13 JP JP2012249078A patent/JP2013075898A/ja not_active Withdrawn
-
2013
- 2013-11-07 NO NO20131483A patent/NO20131483L/no not_active Application Discontinuation
-
2014
- 2014-04-07 US US14/246,830 patent/US20140212481A1/en not_active Abandoned
-
2016
- 2016-06-17 US US15/186,049 patent/US20160297876A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1072947A1 (en) | Immunological methods and compositions for the treatment of alzheimer's disease | |
MXPA05003621A (es) | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. | |
MXPA05008156A (es) | Inmunizacion activa para generar anticuerpos para beta-a soluble. | |
BG104562A (en) | Composition and method for prevention and treatment of amyloidogenic disease | |
TW200617023A (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
HUP0204074A2 (hu) | Abéta peptidet kiválasztó humanizált ellenanyagok | |
WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
EA200501560A1 (ru) | Предотвращение и терапия амилоидогенной болезни | |
PL2087904T3 (pl) | Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem | |
ZA200308767B (en) | Immunogenic peptide composition for the prevention and treatment of alzheimers disease | |
HUP0302589A2 (hu) | A béta-amiloid peptidet felismerő humanizált ellenanyagok | |
MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
ATE397068T1 (de) | Antigene meningokokken peptide | |
MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
DK1553985T3 (da) | Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom | |
MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
RU2353389C2 (ru) | Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций | |
AP1638A (en) | Peptide mimics of conserved gonococcal epitopes and methods and compositions using them. | |
WO2002102849A3 (en) | Bcmp-101, a cancer associated protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160407 |